Search News Archives
IT Solutions and Laboratory Automation
Conferences | Events
LGC acquires Rapid Genomics, bolstering its position in the application of NGS for high-throughput genotyping market in AgBio
LGC announce the acquisition of Rapid Genomics, a provider of mid- to high-density Next-Generation Sequencing (NGS) kits and services for genotyping in the agrigenomics market.
Rapid Genomics is a leading company in genotyping applications via Next-Generation Sequencing (NGS). Its Flex-Seq® Ex-L technology is provided to customers through kits and genotyping services, and allows high-throughput, cost-effective DNA analysis in plant, livestock and aquaculture genetics. This in turn enables development of more productive and resilient plants and animals, as well as food safety and animal health applications through the identification and screening of pathogens.
Mark Dearden, Managing Director, LGC, Biosearch Technologies, said, “We are excited to secure Rapid Genomics, which is an elegant fit with our core purpose of Science for a Safer World. This acquisition will enable future growth and development of our NGS high-throughput offerings in the agrigenomics space. Rapid Genomics is an excellent complement to our existing NGS and PCR genomics capabilities and we look forward to bringing the combined offering to our customers.”
Leandro Neves, CEO and President of Rapid Genomics, said, “We are honoured to join the LGC team. Our companies have worked together for several years with great synergy and shared vision. The access to LGC’s expertise in the field and broad technologies will have a multiplier effect on our ability to provide innovative solutions to our customers. We are excited to be part of LGC and leverage this opportunity to benefit our employees and customers.”
Founded in 2011 in Gainesville, Florida, USA, Rapid Genomics currently has 30 employees.
LGC is a leading, global life science tools company, providing mission-critical components and solutions into high-growth application areas across the human healthcare and applied market segments. Its high quality product portfolio is comprised of mission-critical tools for genomic analysis and for quality assurance applications, which are typically embedded and recurring within our customers' products and workflows and are valued for their performance, quality and range.
LGC's tools play a key role in customer workflows from discovery applications through to commercial manufacture and enable its customers to: bring new diagnostics and therapies to market; progress research and development; optimise food production; and continuously monitor and enhance the quality of food, the environment and consumer products.
LGC's 175+ years of scientific heritage, combined with a track record of innovation and value-enhancing acquisitions, has enabled the company to build its product portfolio and expertise, and develop deep relationships with customers, industry partners and the global scientific community.
LGC's core purpose of Science for a safer world and its core values of passion, curiosity, integrity, brilliance and respect, drive its culture. As of 30 June 2021, it employs 4,350 employees, of which over 1,175 employees hold PhD and/or master's degrees. Its products and services are delivered by highly qualified and experienced teams, operating from a global network of accredited sites that showcase its scientific and manufacturing capabilities.